Table of Content

1. Need For Breast Cancer Immunotherapy?
1.1 Overview
1.2 Breast Cancer Immunotherapy Mechanism Of Action
1.3 Potential Breast Cancer Biomarkers


2. Global Breast Cancer Immunotherapy Market Overview
2.1 Breast Cancer Global Market Insight: Yearly & Quarterly Sales (2019 – 2023)
2.2 Global Breast Cancer Immunotherapy Market Future Outlook (2023 – 2028)


3. Global Breast Cancer Immunotherapy Trend Analysis
3.1 US
3.2 UK
3.3 Canada
3.4 Europe
3.4.1 Germany
3.4.2 France
3.4.3 Italy
3.4.4 Spain
3.4.5 Poland
3.4.6 Belgium
3.5 Australia
3.6 China
3.7 Japan
3.8 South Korea
3.9 India


4. Global Breast Cancer Immunotherapy Approved Drugs Sales, Price, Dosage & Patent Analysis
4.1 Keytruda (Pembrolizumab)
4.2 Perjeta (Pertuzumab)
4.3 Kadcyla (Ado-Trastuzumab Emtansine)
4.4 Phesgo (pertuzumab trastuzumab hyaluronidase)
4.5 Trodelvy (Sacituzumab Govitecan)
4.6 Herceptin (Trastuzumab)
4.7 Enhertu (Fam-Trastuzumab Deruxtecan)
4.8 Margenza (Margetuximab)
4.9 Tecentriq (Atezolizumab)
4.10 Avastin (Bevacizumab)


5. Global Breast Cancer Immunotherapies Clinical Trials Insight
5.1 By Biomarker
5.2 By Company
5.3 By Country
5.4 By Patient Segment
5.5 By Phase


6. Global Breast Cancer Immunotherapies Clinical Trials By Company, Country & Indication
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-II/III
6.7 Phase-III
6.8 Preregistration
6.9 Registered


7. Marketed Breast Cancer Immunotherapies Clinical Insight


8. Therapeutic Approaches To Breast Cancer Immunotherapy
8.1 Monotherapeutic Approaches
8.2 Combination Therapy Approach
8.2.1 Combination Of Targeted Therapy & Endocrine Therapy
8.2.2 Combination With Immunotherapy
8.2.3 Combination Strategies That Include Triple Agents


9. New Immunotherapeutic Approaches In Trials For Breast Cancer Treatment
9.1 Emerging Molecular Targets For CAR T Cell Immunotherapy
9.2 Bispecific Antibodies
9.3 Vaccine Based Therapy
9.4 Oncolytic Viruses
9.5 Immunotherapy with Tumor Infiltrating Lymphocytes (TILs)
9.6 Cytokine Therapy


10. Global Breast Cancer Immunotherapy Market Dynamics
10.1 Market Drivers
10.2 Market Challenges


11. Competitive Landscape
11.1 Amgen
11.2 Antibody Therapeutics
11.3 AstraZeneca
11.4 Biocad
11.5 Bristol-Myers Squibb
11.6 EirGenix
11.7 EpiThany
11.8 Genentech
11.9 ImmunityBio
11.10 LeadArtis
11.11 Mayo Clinic
11.12 Merck
11.13 Novartis
11.14 PACT Pharma
11.15 Pfizer
11.16 Prestige BioPharma
11.17 Protheragen
11.18 Roche
11.19 Samsung Bioepis
11.20 Shanghai Novamab Biopharmaceuticals
11.21 Therabest Korea
11.22 Xuanzhu Biopharmaceutical



List of Figures

 Figure 1-1: Conventional Treatment Strategies Used for Breast Cancer
 Figure 1-2: Classification of Immunotherapy
 Figure 1-3: Different Immunotherapeutic Approaches
 Figure 1-4: Majorly used current biomarkers for Breast Cancer
 Figure 1-5: Emerging and Novel Biomarkers for Breast Cancer
 
Figure 2-1: Global – Breast Cancer immunotherapy Market Sales (US$ Billion), 2019 –
 2023
 Figure 2-2: Global – Breast Cancer immunotherapy Market Quarterly Sales (US$
 Billion)’ 2022
 Figure 2-3: Global – Breast Cancer immunotherapy Market By Drug (US$ Million),
  Q1’2023
 Figure 2-4: Global – Breast Cancer immunotherapy Market By Drug (US$ Million),
 2022
 Figure 2-5: US – Breast Cancer immunotherapy Market (US$ Billion)’ 2019 - 2023
 Figure 2-6: US – Breast Cancer immunotherapy Market By Drug (US$ Million),
 Q1’2023
 Figure 2-7: US – Breast Cancer immunotherapy Market By Drug (US$ Million), 2022
 Figure 2-8: Europe – Breast Cancer immunotherapy Market (US$ Million)’ 2019 –
 2023
 Figure 2-9: Europe – Breast Cancer immunotherapy Market By Drug (US$ Million),
 Q1’2023
 Figure 2-10: Europe – Breast Cancer immunotherapy Market By Drug (US$ Million),
  2022
 Figure 2-11: Global – Breast Cancer immunotherapy Market Sales (US$ Billion), 2023
  - 2028
 
 Figure 3-1: US – Share of Breast Cancer Cases In Total Cancer Cases, 2022
 Figure 3-2: US – Reimbursement System
 Figure 3-3: UK – Share of Breast Cancer Cases In Total Cancer Cases, 2020
 Figure 3-4: UK – Key Reimbursement Stakeholders
 Figure 3-5: Canada – Share of Breast Cancer Cases In Total Cancer Cases, 2020
 Figure 3-6: Canada – Drug Reimbursement Process
 Figure 3-7: Europe – Share of Breast Cancer Cases In Total Cancer Cases, 2020
 Figure 3-8: Germany – Reimbursement Of Drugs
 Figure 3-9: France – Drug Pricing and Reimbursement Process
 Figure 3-10: Italy – Drug Pricing and Reimbursement Process
 Figure 3-11: Spain – Pricing & Reimbursement Process
 Figure 3-12: Poland – Stages Of Reimbursement Decision Making Process
 Figure 3-13: Australia – Drug Payment Process
 Figure 3-14: China – Share of Breast Cancer Cases In Total Cancer Cases, 2020
 Figure 3-15: China – Negotiation Process for National Reimbursement Drug List
 (NRLD)
 Figure 3-16: Japan – Share of Breast Cancer Cases In Total Cancer Cases, 2020
 Figure 3-17: Japan – Reimbursement Process For Public Insured Medical Services
 Figure 3-18: South Korea – Share of Breast Cancer Cases In Total Cancer Cases,
 2020
 Figure 3-19: South Korea – Flow Of Reimbursement Decision making For New Drug
 
 Figure 4-1: Global – Keytruda Annual Sales (US$ Million), 2019 – 2023
 Figure 4-2: Global – Keytruda Quarterly Sales (US$ Million), 2022
 Figure 4-3: US – Keytruda Annual Sales (US$ Million), 2019 – 2023
 Figure 4-4: US – Keytruda Quarterly Sales (US$ Million), 2022
 Figure 4-5: US - Keytruda Price per Unit & per Vial for 25mg/mL Intravenous
 Solution (US$), May’2023
 Figure 4-6: Keytruda – List Price of a Supply for 3 & 6 Weeks (US$), May’2023
 Figure 4-7: Keytruda – Cost of Treatment for Different Administration Schedules,
 May’2023
 Figure 4-8: UK - Keytruda Price per 100mg/4mL Intravenous Solution, May’2023
 Figure 4-9: Keytruda – Patent Expiration Year
 Figure 4-10: Global – Perjeta Annual Sales (US$ Million), 2019 – 2023
 Figure 4-11: Global – Perjeta Quarterly Sales (US$ Million), 2022
 Figure 4-12: US – Perjeta Annual Sales (US$ Million), 2019 – 2023
 Figure 4-13: US – Perjeta Quarterly Sales (US$ Million), 2022
 Figure 4-14: Europe – Perjeta Annual Sales (US$ Million), 2019 – 2023
 Figure 4-15: Europe – Perjeta Quarterly Sales (US$ Million), 2022
 Figure 4-16: Japan – Perjeta Annual Sales (US$ Million), 2019 – 2023
 Figure 4-17: Japan – Perjeta Quarterly Sales (US$ Million), 2022
 Figure 4-18: US – Perjeta per Unit & Price for 420mg/14mL Intravenous Solution
 (US$), May’2023
 Figure 4-19: Perjeta – Total Cost Of Treatment Cycle (US$), May’2023
 Figure 4-20: UK – Perjeta Price per Vial of 420mg/14mL, May’2023
 Figure 4-21: Perjeta – Patent Filing Year v/s Expiration Year – US, Canada &
 Australia
 Figure 4-22: Global – Kadcyla Annual Sales (US$ Million), 2019 – 2023
 Figure 4-23: Global – Kadcyla Quarterly Sales (US$ Million), 2022
 Figure 4-24: US – Kadcyla Annual Sales (US$ Million), 2019 – 2023
 Figure 4-25: US – Kadcyla Quarterly Sales (US$ Million), 2022
 Figure 4-26: Europe – Kadcyla Annual Sales (US$ Million), 2019 – 2023
 Figure 4-27: Europe – Kadcyla Quarterly Sales (US$ Million), 2022
 Figure 4-28: Japan – Kadcyla Annual Sales (US$ Million), 2019 – 2023
 Figure 4-29: Japan – Kadcyla Quarterly Sales (US$ Million), 2022
 Figure 4-30: US – Kadcyla per Unit & Price (US$) For 1 Powder Injection, May’2023
 Figure 4-31: Kadcyla – Cost of Treatment for 100mg & 160mg of Intravenous
 Powder, May’2023
 Figure 4-32: UK - Kadcyla Price per 180mg & 160mg Vial, May’2023
 Figure 4-33: Kadcyla – Patent Expiration Year – US v/s UK
 Figure 4-34: Global – Phesgo Annual Sales (US$ Million), 2020 – 2023
 Figure 4-35: Global – Phesgo Quarterly Sales (US$ Million), 2022
 Figure 4-36: US – Phesgo Annual Sales (US$ Million), 2019 – 2023
 Figure 4-37: US – Phesgo Quarterly Sales (US$ Million), 2022
 Figure 4-38: Europe – Phesgo Annual Sales (US$ Million), 2019 – 2023
 Figure 4-39: Europe – Phesgo Quarterly Sales (US$ Million), 2022
 Figure 4-40: US – Phesgo Price per Unit for 10mL of 20,000 Units Phesgo
 Subcutaneous Injection (US$), May’2023
 Figure 4-41: US – Phesgo Price per Unit for 15mL of 30,000 Units Phesgo
 Subcutaneous Injection (US$), May’2023
 Figure 4-42: Phesgo – Cost of Treatment Cycle (US$), May’2023
 Figure 4-43: UK – Phesgo Price per Unit for 10mL of 600mg/600mg Phesgo
  Subcutaneous Injection, May’2023
 Figure 4-44: UK – Phesgo Price per Unit for 15mL of 1200mg/600mg Phesgo
 Subcutaneous Injection, May’2023
 Figure 4-45: Phesgo – Patent Approval & Expiration Year
 Figure 4-46: Global – Trodelvy Annual Sales (US$ Million), 2021 - 2023
 Figure 4-47: Global – Trodelvy Quarterly Sales (US$ Million), 2022
 Figure 4-48: US – Trodelvy Annual Sales (US$ Million), 2021 –2023
 Figure 4-49: US – Trodelvy Quarterly Sales (US$ Millions), 2022
 Figure 4-50: Europe – Trodelvy Annual Sales (US$ Million), 2021 – 2023
 Figure 4-51: Europe – Trodelvy Quarterly Sales (US$ Millions), 2022
 Figure 4-52: Trodelvy - Per Unit & Price for 180mg of Intravenous Powder (US$),
  May’2023
 Figure 4-53: Trodelvy – Cost of Treatment Cycle (US$), May’2023
 Figure 4-54: UK - Trodelvy Price per 180mg Vial Powder, May’2023
 Figure 4-55: Trodelvy – US v/s UK Patent Expiration Year
 Figure 4-56: Global – Herceptin Annual Sales (US$ Million), 2019 – 2023
 Figure 4-57: Global – Herceptin Quarterly Sales (US$ Million), 2022
 Figure 4-58: US – Herceptin Annual Sales (US$ Millions), 2019 – 2023
 Figure 4-59: US – Herceptin Quarterly Sales (US$ Million), 2022
 Figure 4-60: Europe – Herceptin Annual Sales (US$ Million), 2019 – 2023
 Figure 4-61: Europe - Herceptin Quarterly Sales (US$ Million), 2022
 Figure 4-62: Japan – Herceptin Annual Sales (US$ Million), 2019 - 2023
 Figure 4-63: Japan – Herceptin Quarterly Sales (US$ Million), 2022
 Figure 4-64: US – Herceptin per Unit & Price for 150mg Intravenous Powder For
 Injection (US$)
 Figure 4-65: Herceptin – Cost of Treatment (Schedule 1) (US$), May’2023
 Figure 4-66: Herceptin – Cost of Treatment (Schedule 1) (US$), May’2023
 Figure 4-67: Herceptin – Cost of Treatment for Metastatic HER2 Overexpressing
 Breast Cancer (US$), May’2023
 Figure 4-68: UK – Herceptin Price per Vial for 150mg Powder, May’2023
 Figure 4-69: Herceptin - Patent Filing Year v/s Expiration Year – US & Canada
 Figure 4-70: Global – Enhertu Annual Sales (US$ Million), 2020 – 2023
 Figure 4-71: Global – Enhertu Quarterly Sales (US$ Million), 2022
 Figure 4-72: US – Enhertu Annual Sales (US$ Million), 2020 – 2023
 Figure 4-73: US – Enhertu Quarterly Sales (US$ Million), 2022
 Figure 4-74: EU – Enhertu Annual Sales (US$ Million), 2020 – 2023
 Figure 4-75: EU – Enhertu Quarterly Sales (US$ Million), 2022
 Figure 4-76: Japan – Enhertu Annual Sales (US$ Million), 2020 – 2023
 Figure 4-77: Japan – Enhertu Quarterly Sales (US$ Million), 2022
 Figure 4-78: US - Enhertu per Unit & Price for 100 mg Of Intravenous Powder (US$)
 Figure 4-79: UK– Enhertu Price per 100mg Powder, May’2023
 Figure 4-80: Enhertu – Cost of Treatment With 100mg intravenous Powder,
 May’2023
 Figure 4-81: Margenza – Research & Development Annual Expense (US$ Million),
 2020 - 2022
 Figure 4-82: Margenza –Research & Development Quarterly Expense (US$ Million),
 2022
 Figure 4-83: US - Margenza Price per Unit for 25mg/mL Intravenous Solution (US$),
 May’2023
 Figure 4-84: Margenza – Cost of Treatment with Different Volumes of Intravenous
 Solution, May’2023
 Figure 4-85: Global – Tecentriq Annual Sales (US$ Million), 2019 – 2023
 Figure 4-86: Global – Tecentriq Quarterly Sales (US$ Million), 2022
 Figure 4-87: US – Tecentriq Annual Sales (US$ Million), 2019 – 2023
 Figure 4-88: US – Tecentriq Quarterly Sales (US$ Million), 2022
 Figure 4-89: Europe– Tecentriq Annual Sales (US$ Million), 2019 – 2023
 Figure 4-90: Europe – Tecentriq Quarterly Sales (US$ Million), 2022
 Figure 4-91: Japan – Tecentriq Annual Sales (US$ Million), 2019 – 2023
 Figure 4-92: Japan – Tecentriq Quarterly Sales (US$ Million), 2022
 Figure 4-93: US - Tecentriq Price per Unit for 840mg/14mL & 1200mg/20mL of
 Intravenous Solution (US$), May’2023
 Figure 4-94: UK – Tecentriq Price per Unit for 840mg/14mL & 1200mg/20mL of
 Intravenous Solution, May’2023
 Figure 4-95: Tecentriq – Global Patent Approval & Expiration Year
 Figure 4-96: Global – Avastin Annual Sales (US$ Million), 2019 – 2023
 Figure 4-97: Global - Avastin Quarterly Sales (US$ Million), 2022
 Figure 4-98: US – Avastin Annual Sales (US$ Million), 2019 – 2023
 Figure 4-99: US– Avastin Quarterly Sales (US$ Million), 2022
 Figure 4-100: Europe – Avastin Annual Sales (US$ Million), 2019 – 2023
 Figure 4-101: Europe – Avastin Quarterly Sales (US$ Million), 2022
 Figure 4-102: Japan – Avastin Annual Sales (US$ Million), 2019 -2023
 Figure 4-103: Japan – Avastin Quarterly Sales (US$ Million), 2022
 Figure 4-104: US - Avastin Price per Unit for 25mg/mL of Intravenous Solution
 (US$), May’2023
 Figure 4-105: UK – Avastin Price per Unit for Different Concentrations of Infusion
 Vial, May’2023
 

 Figure 5-1: Global - Breast Cancer immunotherapy Drug Clinical Trials By
 Biomarker, 2023
 Figure 5-2: Global - Breast Cancer immunotherapy Drug Clinical Trials By Company,
 2023
 Figure 5-3: Global - Breast Cancer immunotherapy Drug Clinical Trials By Country,
 2023
 Figure 5-4: Global - Breast Cancer immunotherapy Drug Clinical Trials By Patient
 Segment, 2023
 Figure 5-5: Global - Breast Cancer immunotherapy Drug Clinical Trials By Phase,
 2023

Figure 8-1: Available Monotherapeutic Approaches
Figure 8-2: Available Combinational Therapies

Figure 9-1: Emerging Immunotherapeutic Approaches Currently In Trial

Figure 10-1: Current Market Drivers
Figure 10-2: Current Market Challenges